Patents Assigned to Nerre Therapeutics Limited
  • Patent number: 11872222
    Abstract: This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: January 16, 2024
    Assignee: NeRRe Therapeutics Limited
    Inventors: Mike Trower, Stephen Pawsey, Mary Kerr
  • Publication number: 20230190740
    Abstract: This invention relates to the new use of neurokinin-1(NK-1) receptor antagonists for treating sepsis, septic shock, systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS). The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists and combinations with one or more therapeutic agents, for such uses.
    Type: Application
    Filed: March 30, 2021
    Publication date: June 22, 2023
    Applicant: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • Publication number: 20210369707
    Abstract: This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 2, 2021
    Applicant: NeRRe Therapeutics Limited
    Inventors: Mike Trower, Stephen Pawsey, Mary Kerr
  • Publication number: 20190216806
    Abstract: This invention relates to the new use of the compound (I) or pharmaceutical acceptable salts thereof and pharmaceutical compositions containing it for the treatment of pruritus and to combinations for such a use.
    Type: Application
    Filed: March 27, 2019
    Publication date: July 18, 2019
    Applicant: NeRRe Therapeutics Limited
    Inventors: Emiliangelo Ratti, Michael Trower
  • Patent number: 10195205
    Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: February 5, 2019
    Assignee: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • Patent number: 9907795
    Abstract: This invention relates to the new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-?]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it and one or more therapeutic agents for the treatment of chronic cough, including chronic refractory cough and to combinations for such a use.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: March 6, 2018
    Assignee: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • Publication number: 20170326140
    Abstract: This invention relates to a new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of Interstitial lung diseases (ILDs), including IPF, and to combinations for such uses.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 16, 2017
    Applicant: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • Patent number: 9750739
    Abstract: This invention relates to the new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of chronic cough, including chronic refractory cough and to combinations for such a use.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: September 5, 2017
    Assignee: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • Publication number: 20170196860
    Abstract: This invention relates to the new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of chronic cough, including chronic refractory cough and to combinations for such a use.
    Type: Application
    Filed: December 27, 2016
    Publication date: July 13, 2017
    Applicant: NeRRe Therapeutics Limited
    Inventor: Mike Trower
  • Patent number: 9603849
    Abstract: This invention relates to the new use of the compound (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of pruritus and to combinations for such a use.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: March 28, 2017
    Assignee: NERRE THERAPEUTICS LIMITED
    Inventors: Emiliangelo Ratti, Michael Trower
  • Patent number: 9006271
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C1-4 alkyl useful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: April 14, 2015
    Assignee: Nerre Therapeutics Limited
    Inventors: Giuseppe Alvaro, Agostino Marasco
  • Publication number: 20140249188
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C1-4 alkyl useful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 4, 2014
    Applicant: NERRE THERAPEUTICS LIMITED
    Inventors: Giuseppe ALVARO, Agostino MARASCO
  • Patent number: 8822504
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C1-4 alkyl useful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: September 2, 2014
    Assignee: Nerre Therapeutics Limited
    Inventors: Giuseppe Alvaro, Agostino Marasco
  • Patent number: 8796269
    Abstract: The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: August 5, 2014
    Assignee: Nerre Therapeutics Limited
    Inventors: Andrew Simon Craig, Salima Zarah Ismail, Ronnie Maxwell Lawrence
  • Patent number: 8633214
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof processes for their preparation, compositions containing them, and uses thereof in the treatment of diseases and conditions for which antagonism of NK1 is beneficial.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: January 21, 2014
    Assignee: Nerre Therapeutics Limited
    Inventors: Giuseppe Alvaro, Emiliano Castiglioni, Agostino Marasco